Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 2/20 | 0.30 |
| ▸ | PPARA | Q07869 | 2/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148492 | 0.81 | KDM4C (0.31) | — | |
| SCHEMBL5148463 | 0.81 | TRPV1 (0.32) | ITGB1ITGA4 | |
| SCHEMBL2978167 | 0.81 | ITGB1 (0.45) | DRD1FFAR1ITGB1ITGA4PPARG | |
| SCHEMBL2978173 | 0.81 | ITGB1 (0.45) | DRD1FFAR1ITGB1ITGA4PPARG | |
| SCHEMBL2978120 | 0.76 | ITGB1 (0.42) | DRD1FFAR1ITGB1ITGA4PPARG | |
| SCHEMBL7259000 | 0.74 | DRD1 (0.37) | DRD1FFAR1ITGB1ITGA4P2RX7 | |
| SCHEMBL5148581 | 0.73 | FFAR1 (0.36) | DRD1FFAR1ITGB1ITGA4 | |
| SCHEMBL5574241 | 0.72 | ITGB1 (0.51) | DRD1FFAR1ITGB1ITGA4PPARG | |
| SCHEMBL2982542 | 0.72 | ITGB1 (0.51) | DRD1FFAR1ITGB1ITGA4PPARG | |
| SCHEMBL6537418 | 0.71 | ITGB3 (0.45) | DRD1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | UCB PHARMA S.A. (BE) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | ITGB2, VCAM1, ITGB1 | DRD1 3101/4885FFAR1 151/4885ITGB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.